We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Adamas Wins Approval of Drug for Dyskinesia in Parkinson’s Patients
Adamas Wins Approval of Drug for Dyskinesia in Parkinson’s Patients
The FDA approved Adamas Pharmaceuticals’ Gocovri (amantadine) for the treatment of dyskinesia in Parkinson’s disease patients receiving levodopa therapy, making it the first drug to be approved for that condition.